U.S. markets open in 3 hours 29 minutes
  • S&P Futures

    3,855.00
    +35.75 (+0.94%)
     
  • Dow Futures

    31,936.00
    +160.00 (+0.50%)
     
  • Nasdaq Futures

    12,548.00
    +250.75 (+2.04%)
     
  • Russell 2000 Futures

    2,233.20
    +32.40 (+1.47%)
     
  • Crude Oil

    65.69
    +0.64 (+0.98%)
     
  • Gold

    1,699.40
    +21.40 (+1.28%)
     
  • Silver

    25.73
    +0.46 (+1.82%)
     
  • EUR/USD

    1.1905
    +0.0052 (+0.44%)
     
  • 10-Yr Bond

    1.5960
    0.0000 (0.00%)
     
  • Vix

    24.69
    +0.03 (+0.12%)
     
  • GBP/USD

    1.3879
    +0.0057 (+0.41%)
     
  • USD/JPY

    108.7480
    -0.1530 (-0.14%)
     
  • BTC-USD

    54,168.54
    +4,303.21 (+8.63%)
     
  • CMC Crypto 200

    1,094.19
    +69.98 (+6.83%)
     
  • FTSE 100

    6,751.34
    +32.21 (+0.48%)
     
  • Nikkei 225

    29,027.94
    +284.69 (+0.99%)
     

Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Phathom Pharmaceuticals
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 3:30 p.m. ET on Tuesday, September 15, 2020.

Company management will also participate in one-on-one meetings during the virtual conference which runs from September 14-18, 2020.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 60 days following the event.

About Phathom
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the Company’s website at www.phathompharma.com or follow the Company on LinkedIn at www.linkedin.com/company/phathompharma.

CONTACTS

Media Contact:
Nick Benedetto
1-877-742-8466
media@phathompharma.com

Investor Contact:
Todd Branning
1-877-742-8466
ir@phathompharma.com